Guess which ASX All Ords share is soaring 12% on a 'key step'

A positive update is getting investors very excited. What did the company announce?

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Race Oncology Ltd (ASX: RAC) share price is having a very strong session.

In morning trade, the ASX All Ords share is up an impressive 12% to 86 cents.

Why is this ASX All Ords share rising?

Investors have been buying the oncology company's shares after it released an update on its novel bisantrene formulation, RC220.

According to the release, the company has successfully completed a series of preclinical animal and laboratory studies showing that RC220 prevents drug precipitation (crystallisation) and phlebitis (vein inflammation or damage) when infused into peripheral veins.

These studies were performed in vivo and in vitro at Pharmaron in California and by Race Oncology scientists at the University of Wollongong.

Why is this important?

The current administration of bisantrene requires the use of an invasive central venous catheter and must be performed in a hospital setting.

While this approach is common practice for the delivery of chemotherapy drugs in patients with haematological cancers, it is not standard practice for solid tumours, such as breast cancer, where peripheral IV infusions in an outpatient setting are typically preferred by both the patient and the treating oncologist.

RC220 could potentially open the door to bisantrene being administered in an outpatient setting.

The ASX All Ords share' executive director, Dr Pete Smith, was pleased with the news. He commented:

Given the creativity, hard work and capital we have invested into RC220, it is gratifying to see the formulation perform as designed, preventing bisantrene peripheral vein precipitation and phlebitis in industry standard preclinical models expected by regulators. This is a key step on our path to bringing a superior version of bisantrene to the clinic for the benefit of a much larger number of patients with solid tumours and the clinicians who treat them. With RC220 also comes additional, robust intellectual property that adds significant commercial value to Race.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »